Guggenheim Initiates Coverage On Mersana Therapeutics with Buy Rating, Announces Price Target of $14
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Michael Schmidt initiates coverage on Mersana Therapeutics (NASDAQ:MRSN) with a Buy rating and announces a price target of $14.
June 15, 2023 | 8:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim initiates coverage on Mersana Therapeutics with a Buy rating and a price target of $14.
The Buy rating and price target of $14 announced by Guggenheim analyst Michael Schmidt for Mersana Therapeutics (MRSN) is likely to have a positive short-term impact on the stock price. The coverage initiation by a reputable analyst and the price target above the current market price indicate a positive outlook for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100